Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-3100 for HPV-related Cervical HSIL (REVEAL 2)
NCT03721978Phase 3Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Feb 2019
- Primary completion
- Aug 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines, Cancer Vaccines
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Squamous Intraepithelial Lesion (SIL) comparing VGX-3100 + EP with Matched Placebo + EP (2 arms). Primary endpoint: Percentage of Participants With No Histologic Evidence of Cervical HSIL and No Evidence of HPV-16 and/or HPV-18 at Week 36. Started Feb 2019; status: completed.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT03721978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721978.